Checked
Decoy Therapeutics Inc.
Nasdaq: DCOY · Pharmaceutical Preparations · Houston, TX
- Net income
- -$12.52M
- Total assets
- $11.06M
- Diluted EPS
- -$129.10
Company details
As reported to the SEC
- SEC CIK
- 1615219
- Stock
- Nasdaq: DCOY
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- 2450 Holcombe Blvd, Suite J-608, Houston, TX 77021
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (346) 772-0346
- Employer ID (EIN)
- 46-5087339
- Last annual report
- 03/31/2026
- Last quarterly report
- 08/12/2026
Formerly: Salarius Pharmaceuticals, Inc. (until 01/09/2026); Flex Pharma, Inc. (until 07/22/2019)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | Not reported | Not reported | Not reported | $0 | $1.84M |
| Operating income | -$12.61M | -$5.73M | -$12.89M | -$31.84M | -$12.81M |
| Net income | -$12.52M | -$5.58M | -$12.54M | -$31.61M | -$12.77M |
| Diluted earnings per share | -$129.10 | -$69.54 | -$30.74 | -$14.88 | -$7.72 |
| Research and development | $368.2K | $770K | $7.17M | $15.84M | $8.55M |
| Total assets | $11.06M | $3.02M | $6.59M | $14.65M | $40.83M |
| Total liabilities | $5.17M | $1.51M | $1.3M | $4.27M | $2.11M |
| Shareholders' equity | $5.89M | $1.51M | $5.29M | $10.38M | $38.72M |
| Cash and cash equivalents | $10.71M | $2.43M | $5.9M | $12.11M | $29.21M |
| Cash from operations | -$4.83M | -$4.53M | -$12.85M | -$17.6M | -$10.2M |
| Capital expenditures | Not reported | Not reported | Not reported | Not reported | $0 |
Recent filings
144 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
17 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Decoy Therapeutics Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Decoy Therapeutics Inc.'s CIK number?
- Decoy Therapeutics Inc.'s SEC Central Index Key (CIK) is 1615219.
- What is Decoy Therapeutics Inc.'s stock ticker?
- Decoy Therapeutics Inc. trades as Nasdaq: DCOY.
- When does Decoy Therapeutics Inc.'s fiscal year end?
- Decoy Therapeutics Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Decoy Therapeutics Inc. headquartered?
- Decoy Therapeutics Inc.'s principal executive office on file with the SEC is in Houston, TX.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026